00:35 , Jul 13, 2019 |  BioCentury  |  Product Development

Why Merck is in infectious disease for the long haul

Merck is bucking the trend of its biopharma peers by continuing to invest in and build its infectious disease pipeline. With new regulatory pathways in play and novel funding mechanisms for antibiotics starting to take...
23:45 , Apr 16, 2019 |  BC Extra  |  Company News

Achaogen files for bankruptcy amid continued headwinds for antibiotic developers

Following regulatory headwinds and what it called very limited uptake of its sole marketed antibiotic, Achaogen filed for Chapter 11 bankruptcy late Monday. It is one of several antibiotic companies that have lost over half...
13:15 , Apr 1, 2019 |  BC Innovations  |  Emerging Company Profile

Arixa: Breaking resistance with oral beta lactamase inhibitors

Arixa has made an IV antibiotic oral with prodrug chemistry. Arixa Pharmaceuticals Inc. is modifying diazabicyclooctanes, a class of β-lactamase inhibitors that suffer from poor absorption across the GI tract, for use in combination with...
19:31 , Feb 7, 2019 |  BC Extra  |  Tools & Techniques

Virtual compound library for high throughput computational drug discovery

University of California San Francisco researchers have launched an updated, publicly available and growing virtual library of over 350 million small molecules, all of which can be synthesized on demand. Combined with high throughput computational...
15:56 , Oct 26, 2018 |  BioCentury  |  Finance

Rempex remix

New Enterprise Associates led Qpex Biopharma Inc.’s $33 million A round in hope that the management team will repeat its performance at Rempex Pharmaceuticals Inc. and The Medicines Co. (NASDAQ:MDCO) with a preclinical anti-infectives portfolio....
20:48 , Oct 5, 2018 |  BC Week In Review  |  Company News

Boston Pharmaceuticals licenses three Novartis antibacterials, five GSK programs

Boston Pharmaceuticals Inc. (Cambridge, Mass.) in-licensed eight products through a pair of deals with Novartis AG (NYSE:NVS; SIX:NOVN) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Boston acquired exclusive, global rights to three anti-infective compounds from Novartis for...
14:29 , Oct 3, 2018 |  BC Extra  |  Company News

Boston Pharmaceuticals licenses three Novartis antibacterials, five GSK programs

Boston Pharmaceuticals Inc. (Cambridge, Mass.) in-licensed eight products through a pair of deals with Novartis AG (NYSE:NVS; SIX:NOVN) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Boston acquired exclusive, global rights to three anti-infective compounds from Novartis for...
18:18 , Sep 28, 2018 |  BC Week In Review  |  Company News

Everest adds another antibiotic to pipeline through VenatoRx deal

C-Bridge-backed Everest Medicines Ltd. (Shanghai, China) will receive exclusive rights from VenatoRx Pharmaceuticals Inc. (Malvern, Pa.) to develop and commercialize VNRX-5133 in combination with cefepime. The deal covers Greater China, South Korea and Southeast Asia...
18:01 , Sep 28, 2018 |  BC Week In Review  |  Financial News

Entasis raises $75M in IPO

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) fell $4.34 (29%) to $10.66 on Sept. 26 after it raised $75 million through the sale of 5 million shares at $15 in its IPO. The offering price valued Entasis...
17:25 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

CHMP backs Luxturna, Lilly's migraine mAb, antibiotic Vabomere

EMA's CHMP on Sept. 21 recommended several therapies for approval, including gene therapy Luxturna voretigene neparvovec, migraine mAb Emgality galcanezumab and antibiotic Vabomere meropenem/vaborbactam. CHMP also confirmed its negative opinion for Exondys eteplirsen from Sarepta...